Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-MAGE-A4
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
SC-MAGE-A4 is an investigational autologous T-cell receptor (TCR) therapy engineered to target the Melanoma-associated antigen A4 (MAGE-A4) peptide presented by HLA-A*02. Developed by 2seventy bio in collaboration with Regeneron, the therapy incorporates a proprietary TGF-beta "flip" receptor (TGFβRII-41BB). This chimeric receptor is designed to convert the immunosuppressive TGF-beta signal commonly found in the tumor microenvironment into a pro-inflammatory and stimulatory signal via the 4-1BB costimulatory domain. This engineering approach aims to enhance the expansion, persistence, and anti-tumor potency of the engineered T cells against solid tumors. In early 2024, Regeneron acquired 2seventy bio's full oncology pipeline, including the SC-MAGE-A4 program, while JW Therapeutics maintains regional rights for Greater China.
- Other names
- MAGE-A4 TCR therapyMAGE-A-4 TCR therapyMAGE-A 4 TCR therapyMAGE-A4 TCR-T cell therapyMAGE-A-4 TCR-T cell therapyMAGE-A 4 TCR-T cell therapy2seventy bio MAGE-A4 TCR
02
Targets
MAGE-A4 peptide-HLA-A*02:01 complexTNFRSF9 (CD137 extracellular domain)CTBR12 (Transforming growth factor beta receptor type II / Interleukin-12 receptor beta 2 chimeric receptor)
Beyond the preview
Go deeper on SC-MAGE-A4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-MAGE-A4.